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doi:10.1016/j.bpobgyn.2012.01.005The distinctive feature of the human immunodeficiency virus
(HIV) epidemic in Sub-Saharan Africa is the burden on women, in
particular young women of reproductive age. Consequently, most
late-phase effectiveness microbicide clinical trials are conducted in
sub-Saharan Africa where fertility rates are high. Because late-
phase clinical trials are conducted over prolonged periods of
time, women participating in these trials may fall pregnant during
the trial. Their unborn babies may be exposed to a drug whose
teratogenic potential is unknown if the investigational drug is not
withdrawn. High pregnancy rates in such trials may compromise
statistical integrity, as women will be withdrawn from the study
drug for the duration of the pregnancy. It is therefore imperative
for microbicide trials to implement effective contraceptive and
pregnancy management programmes that maintain low preg-
nancy rates and the safety of unborn babies while not compro-
mising the conduct and statistical integrity of the trial.
 2012 Elsevier Ltd. All rights reserved.Introduction
A distinctive feature of the human immunodeficiency virus (HIV) epidemic in the 21st century is its
increasing burden inwomen, particularly young women. Women now account for about one-half of all
people living with HIV, and for more than 60% of new infections in Africa, where heterosexual19; Fax: þ44 (0) 1865 222502.
k (S. Sibeko).
d. All rights reserved.
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young women in the reproductive age group bearing the brunt of the epidemic. This is also the region
where fertility rates are high as a result of cultural norms and expectations, and where socio-cultural
gender dynamics prevail in sexual relationships. This affects a woman’s ability to make independent
decisions about her sexual and reproductive health, often negatively.
Barrier contraceptive methods are an effective HIV and pregnancy prevention strategy; however,
many women in Africa are unable to negotiate successfully their use with male partners, often for
socio-cultural reasons. Therefore, a method that women can initiate or control is urgently required. As
a result of the shortfall of barrier contraceptive methods to protect women against HIV acquisition,
a topical virucide that could block HIV transmission by the vaginal route was suggested as an alter-
native strategy in 1990.2 Since then, three generations of various intravaginally administered micro-
bicides, with varyingmechanisms of actions, have been tested. To date, one antiretroviral-based and 12
non-antiretroviral-based microbicide effectiveness trials among women have taken place to assess
their effect on the prevention of HIV infection, with varying success rates3 (Table 1). The 14th trial
implemented in 2009 is currently ongoing, and its results are anticipated early in 2013.4 The most
recent to be implemented is the South African study, FACTS 001, with an anticipated completion date
in 2013.5
One of the greatest challenges in conducting these trials has been the associated high pregnancy
rates.6–8 In clinical trials of experimental drugs where teratogenic effects on the fetus are not fully
understood, participants who become pregnant during the trial may be taken off the product for safety
reasons. Microbicides are relatively new developmental drugs whose pharmacokinetics and phar-
macodynamics are not completely understood. They act locally, however, and their systemic absorp-
tion is either minimal and transient or unlikely, and trans-placental fetal exposure via systemic
circulation is therefore likely to be insignificant. Taking pregnant women off the study drug may be
a prudent cautionary option, as no specific guidelines are available for their inclusion in late-phase
clinical trials. In microbicide trials, high pregnancy rates with discontinued product use have impli-
cations for the design, conduct and generalisability of the results, including the loss of power and effect
size of the study outcome in an intention-to-treat analysis.7
To address the challenges of high pregnancy rates and potential adverse pregnancy-related
outcomes, various trials have implemented different strategies with varying levels of success.
Although some trials reported pregnancy rates as high as 64 per 100 person years with time off product
loss as high as 151 per 100 person years,9 recently completed trials have achieved pregnancy rates as
low as four per 100 person years with negligible time off product lost.10 In this publication, strategies
used by previously completed trials to enhance contraceptive use and reduce pregnancy rates while
maintaining the safety of the fetus are reviewed. The successes and failures based on the respective
strategies as measured by contraceptive uptake and pregnancy rates are compared. On the basis of
these outcomes, strategies that may be selected for future use in these trials are recommended, and
gaps in current knowledge are identified.
Contraceptive use management
Need for a contraceptive programme
Of the estimated 208 million pregnancies that occurred in 2008, about 86 millionwere unintended,
of which 33 million resulted in unplanned births, 41 million in abortions, and the remaining 11 million
in spontaneous miscarriages.11 Although some unintended pregnancies occur in women on a contra-
ceptive method as a result of method failure with either typical or perfect use, others occur in women
who are not on a contraceptive method at all. Outside of research, almost one-half of unintended
pregnancies occur in women not on any contraceptive method. The Guttmatcher researchers reported
that, in 2001, almost one-half of the 6.4 million pregnancies in the USAwere unintended and, in 52% of
these, no contraceptive method was used during themonth of conception.12 It is essential, therefore, to
prevent or reduce unintended pregnancies and minimise the sequalae on the efficiency of trial
conduct and statistical integrity. An intensive contraceptive programme has to be implemented in any
microbicide trial.
Table 1
Microbicide trials to date.














Kenya N-9 Sponge Trial13 N-9 III 138 116a – Female sex worker 1987–1990 Kenya
FHI N-9 Film Trial14 N-9 III 1292 1170a 18–45 Female sex worker 1994– 1996 Cameroon
Low-dose N-9 gel Trial15 N-9 III 278 262a 18–48 Female sex worker 1996– 1998 Kenya
UNAIDS COL-1492 Trial16 N-9 II/III 892 765a over 18b Female sex worker 1996–2000 Benin, Côte d’Ivoire,
South Africa, Thailand
FHI Savvy Trial/Ghana9 C31G III 2142 2038a 18–35 Sexually active 2004–2005 Ghana




Cellulose sulfate III 1147 1122a over 18 Sexually active 2005–2007 Benin, India, South
Africa, Uganda
FHI CS Trial18 Cellulose sulfate III 1644 1506a 18–35 Sexually active 2004–2007 Nigeria
Population Council
Carraguard Trial25
Carraguard III 6202 6005d over 16 Sexually active 2004–2007 South Africa
MDP 301 (0.5% & 2% PRO
2000)26
PRO 2000 III 9385 8859a over 18e Sexually active 2005–2008 South Africa, Tanzania,
Uganda and Zambia










Tenofovir II/IIb 1085 889f 18–40 Sexually active 2007–2010 South Africa
MTN 003 VOICE Trial4 Tenofovir IIb Ongoing Ongoing 18–45 Sexually active 2009– Present South Africa, Uganda,
Zimbabwe
FACTS 001 Trial5 Tenofovir III Ongoing Ongoing 18–30 Sexually active 2011–Present South Africa
CAPRISA, Centre for the AIDS Programme of Research in South Africa; CONRAD, Contraceptive Research and Development; FACTS, Follow-on African Consortium for Tenofovir Studies; FHI,
Family Health International; HPTN, HIV Prevention Trials Network; N-9, Nonoxynol-9; MDP, Microbicide Development Programme; MTN, Microbicide Trials Network; VOICE, Vaginal and
Oral Interventions to Control the Epidemic.
Dash: Data not available.
a Sample size based on a subset of the intent-to-treat population for whom at least one post-enrollment HIV evaluation is available.
b In South Africa the age was 16 years or older.
c Data from the two sites in India (Chennai, Bangalore) were not included in this analysis because only two pregnancies were observed in those sites and because of the high prevalence of
surgical sterilisation. See Halpern et al (2011).31
d Individuals were excluded from the analysis if they did not have at least one post-enrolment HIV evaluation, if they had window period seroconversion, or if they only returned unused
applicators.
e In Tanzania and Uganda, the age was 16 years or older.
f Individuals were excluded from the analysis if they they did not have at least one post-enrolment HIV evaluation, were co-enrolled in another microbicide trial, were in a microbicide


















S. Sibeko et al. / Best Practice & Research Clinical Obstetrics and Gynaecology 26 (2012) 473–486476Besides the mismatch in pregnancy intentions and contraceptive use behaviour, women may not
be on a contraceptive method for other reasons, including poor access and availability owing to high
cost and unavailable or limited family planning services. It is important that microbicide trials endorse
strategies that make contraceptives widely accessible and available, but also accentuate contraceptive
uptake and use. Researchers conducting microbicide trials should promote the use of highly effective
and reliable contraceptives throughout the study period in order to keep rates of unplanned and
unwanted pregnancies to a minimum. Strategies from screening and enrolment through to follow
up and exit visits have been used by various microbicide studies with varying degrees of success
(Table 2).
Eligibility criteria
Early trials implemented before 2007 studying the first two generations of non anti-retroviral-
based microbicides (i.e. the surfactants and polymers), did not specify contraceptive use as an
eligibility criterion for trial participation (Table 2). Perhaps that was understandable given that
some of the earlier microbicide agents such, as nonoxynol 9,13–16 a spermicide, and cellulose
sulphate,17,18 an entry inhibitor, also possessed a primary underlying contraceptive effect.12 Preg-
nancy rates were not high in the nonoxynol 9 trials, and were found to be comparable to those of
cellulose sulphate (CS) as established in a (CS) non-comparative trial.19 In addition, this was in the
early days of microbicide trials before the scale of the effect of high pregnancy rates could be
appreciated. A first meeting of experts to discuss pregnancy-related challenges in microbicide trials
was convened in 2005. This was a culmination of lessons learned from ongoing trials in the field,
with pregnancy rates as high as 64 and 37 per 100 person years overall in the Savvy/Ghana and
Savvy/Nigeria trials, respectively9,20 and 76 per 100 person years in one of the Ghana sites.8 In the
meeting, a recommendation to specify contraceptive-related eligibility criteria among others was
made.6 Subsequent discussions by experts in the field occurred at the 2006 microbicide conference
in Cape Town,8 and again at the pregnancy and contraception in microbicide clinical development
meeting in 2009.21
Microbicide trials implemented after this era, such as CAPRISA 004 implemented in 2007,10 MTN
003 implemented in 2009,4 and FACTS 001 implemented in 2011,5 specified contraceptive-related
eligibility criteria, including enrolment of women on a pre-specified eligible type of contraceptive
method. To date, CAPRISA 00410 is the only published study that included contraceptive use as an
eligibility criteria and enrolled womenwith documented evidence of contraceptive use (Table 2). These
women were counselled. If they voluntarily opted for contraceptive use at screening, they were
commenced on a contraceptive method. Consequently, it is the only study with 100% contraceptive
uptake at baseline.22
Recent studies on microbicides have used various specifications to define an eligible method of
contraception, ranging from reliable to effective to non-barriermethods. The definition of an “effective”
method was based on the conventional typical use rates characterised by a pregnancy risk of 3% or less
in the first year of use.23 Additionally, in the context of these trials, other attributes to considerwould be
a method that is less user dependant, less likely to be used inconsistently, and with less provider
training requirements.6 The CAPRISA 00410 trial had inclusion criteria for non-barrier methods of
contraception. This strategy was based on the high probability of inconsistent use of barrier methods
which could result in higher pregnancy rates. Barrier methods, however, were promoted and supplied
widely, but were promoted as part of risk-reduction counselling to reduce the acquisition and trans-
mission of sexually transmitted infections, HIV and other reproductive infections. This strategy was
included in the comprehensive contraceptive curriculum used and implemented by the CAPRISA 004
trial,10 which achieved around 80% uptake of long-acting injectable contraceptive methods during
the trial.22
Some concerns have been raised with pre-specifying contraceptive eligibility criteria. One
concern is that it may compromise enrolment targets. This was not evident in CAPRISA 004,10
however. Of the total number of 2160 women screened, only 26 out of 1075 women did not fulfil the
criteria of trial entry of not being on an eligible contraceptive method.22 Another ethical concern
with pre-specifying contraceptive-related eligibility criteria is that it might be misinterpreted as
Table 2
Contraception management in microbicide trials to date.






























Kenya N-9 Sponge Trial13 No No – 25 – – – Monthly Exit No – – –
FHI N-9 Film Trial14 No No 87a – 5a,b – – 8a Monthly – No – – –
Low-dose N-9 gel Trial15 No No 49 14 15 11 7 Monthly – No – – –
UNAIDS COL-1492 Trial16 No No – – – – – Monthly – No – – –
FHI Savvy Trial/Ghana9,d No No 39a 12a 2a 47a 0.6a Monthly – No – Family planning
counsellingc
–






No No 13a 8a 24a 47a 9a Monthly – Yese Yes OCPs, Injectables –





No No 23 8 42 18 14 Quarterly Quarterly Yese Yes OCPs, injectables 20
MDP 301 (0.5% and 2% PRO
2000)26
No No – – 56g – – – Monthly – Yes Yes OCPs, injectables, IUDh –
HPTN 035 0.5% PRO 2000 and
Buffergel Trial24,i
No No – 20 48 – – Monthly Quarterly Yese Yes OCPs, injectables –
Antiretroviral drugs
CAPRISA 004 Tenofovir gel
Trial10,22
Yes Yesj 0 16 82 29 2 Monthly Monthly Yes Yes OCPs, injectables, IUD,h
tubal ligationh
5
MTN 003 VOICE Trial4 Yes Yesj Ongoing Ongoing Ongoing Ongoing Ongoing Monthly Monthly Yes Yes Contraception Servicesk Ongoing
FACTS 001 Trial5 Yes Yesj Ongoing Ongoing Ongoing Ongoing Ongoing Monthly Quarterly Yes Yes OCPs, injectables, IUD,h
sterilisation,h implantsh
Ongoing
CAPRISA, Centre for the AIDS Programme of Research in South Africa; CONRAD, Contraceptive Research and Development; FACTS, Follow-on African Consortium for Tenfovir Studies; FHI, Family Health International; HPTN, HIV
Prevention Trials Network; IUD, Intrauterine Device; MDP, Microbicide Development Programme; MTN, Microbicide Trials Network; N-9, nonoxynol-9; OCP, oral contraceptive pills; VOICE, Vaginal and Oral Interventions to Control
the Epidemic.
Dash: Data not available.
a Percentages were calculated using the primary-analysis population.
b 5% was reported for ‘hormonal’ contraception, which included OCPs and injectables.
c Family planning counselling was provided with referral to services if requested.
d Data were supplemented with information from Halpern et al. (2011).31
e Trials began with contraception not always provided on site and then changed to on-site management.
f Data were supplemented with information from Friedland (2009).36,39
g 56% of the population was considered to have ‘effective contraception’, which included sterilisation, IUD, or use of injected, implanted or oral contraception.
h Referred to family planning clinics.
i Data were supplemented with information from Abdool Karim (2007).37
j Effective contraception for enrollment includes non-barrier methods such as hormonal (oral, injectable), IUD, and sterilisation.
k Study staff will provide contraceptive counselling to enrolled participants as needed throughout participation and will facilitate access to contraceptive services through direct service delivery.
S. Sibeko et al. / Best Practice & Research Clinical Obstetrics and Gynaecology 26 (2012) 473–486478mandating a certain contraceptive method among women who are interested in participating in
a trial but who would prefer to use a non-eligible method. To date, no consensus on this has been
achieved. Unless there is evidence to the contrary, this strategy is recommended for implementation
in clinical trials, as it ensures enrolment of women less likely to default taking contraceptive
methods.
On-site provision of free contraceptives
Accessibility and availability of contraceptive facilities and methods are not always optimal in
countries in which these trials are conducted. It might be problematic to therefore prescribe contra-
ceptive practices within a study when the pre-specified methods are neither accessible nor available,
or they are not provided as per the local national contraceptive programmes. It is therefore in the best
interest of the trial sites to provide eligible methods as well as ongoing care and counselling that are
necessary with such a service. Providing family planning services within clinical trials, however, poses
extra burdens on the trial resources and infrastructure. This is a specialised service necessitating staff
training to provide and switch methods when indicated, manage complications, and to maintain
a constant supply. Implementation of this service has proven to be a necessary and rewarding trade-off,
as direct temporal effects have been seen in lowering pregnancy rates after implementation of on-site
contraceptive provision.
Studies or sites within studies that have introduced on-site provision of contraceptives from
the beginning10 or sometime during the study24–26 have achieved either the lowest or drastic
declines in their pregnancy rates after implementation of this strategy. The latter was seen with
some sites of the Population Council’s Carraguard, HPTN 035 and MDP 301 trials.24–26 The
Population Council’s South Africa sites observed declines in pregnancy rates after revising their
contraceptive strategy to include on-site provision after high-incident pregnancies between 2004
and 2005.
At the Medical University of Southern Africa, the incidence decreased from 60 in 2005 to 23 per 100
person years in 2006. At the Medical Research council and University of Cape Town, a decrease in rates
from 51 and 43 in 2005 to 32 and 14 per 100 person years in 2006, respectively, were clearly evident.27
Similarly, the pregnancy rates in the Microbicide Development Programme 301’s Zambia site
decreased stepwise from 23% to 18,6% to 12,9% after implementation of contraceptive provision, family
planning checklists and training of staff on counselling.28 All these studies, however, emphasised one
thing in common; the implementation of free on-site provision combined with training of staff and
ongoing counselling of participants were together effective in increasing contraceptive uptake and
reducing pregnancy rates.
Ongoing counselling by trained staff within clinical trials
Counselling by trained clinical trial staff is an important part of offering contraceptive services, as it
affords an opportunity to assess compliance, manage complications and adverse events, and guide
method switching. This is important, as it has previously been reported that ineffective contraceptive
use, rather than non-use, contributes to unintended pregnancy.29 In high-income countries, it has been
reported that most women undergo legal termination of pregnancy as a result of contraceptive failure,
whereas only a small proportion are caused by non-use of contraception. In Eastern European and
South Asian countries, as many as two-thirds of abortions are due to contraceptive failure, and one-
third are due to unmet needs for contraception.30
In CAPRISA 004,10 method switching and the oral contraceptive pill use were significantly associ-
ated with high pregnancy incidence.22 Because of ongoing monitoring of contraceptive usage at
monthly counselling sessions, the need for additional counselling to participants on oral contraceptives
owing to the high number of pregnancies that resulted because of inconsistent usewas identified. Once
implemented, these measures improved adherence to contraception as uptake remained high, and
kept pregnancy rates reasonably low, with only 5% of the women not on a documented contraceptive
method at study exit (Table 2). In the Population Council’s Carraguard trial,25,27 only 20% were not on
a contraceptive method after modification of the contraceptive guidelines to provide support to
S. Sibeko et al. / Best Practice & Research Clinical Obstetrics and Gynaecology 26 (2012) 473–486 479women. In the MDP Zambia site, pregnancy rates dropped from 23 to 12.9% within 16 months after
implementing counselling coupled with on-site provision.26,28 This indicates that developing
a contraceptive curriculum that is tailor made to suit the needs of the participants is effective in
keeping contraceptive uptake and use high in a clinical trial.
Investigators from CAPRISA 004,10 Microbicide Development Programme 301,26 HIV Prevention
Trials Network 035,24 and Population Council25 concluded that the targeted contraceptive curriculum
significantly enhanced contraceptive uptake and use, and recommended therefore that future
microbicide trials should factor the implementation of these comprehensive curriculums in their
protocol development and budgets.Pregnancy management
Need for pregnancy management
Incidental pregnancies during microbicide trials pose numerous challenges, including the
possibility of compromising maternal and fetal safety and statistical integrity. In most microbicide
trials, pregnancy is an indication to either terminate further study participation or stop the study
product, and resume it once the pregnancy chemical tests on urine, blood, or both, revert to being
negative. Delayed pregnancy diagnosis may result in inadvertent teratogenecity and adverse preg-
nancy outcomes. Deferred product resumption after cessation for a pregnancy state may result in
unnecessary increases of time off product, whereas pre-clinical pregnancy losses may delay product
resumption, with pregnancy rates therefore needing to be kept at a minimum. Some of these
challenges are inherent from the demographic characteristics of the population studied, whereas
others are inherent from the design of the clinical trial and the route of administration of the study
drug. Paradoxically, other challenges result from strategies used to address or minimise the above
issues.
The participants in microbicide trials are usually young, sexually active women, who are at high risk
of HIV infection as they reside in regions where unprotected heterosexual intercourse is the driver of
the epidemic. They are, therefore, concurrently at high risk of falling pregnant as they are in their
biologically fertile years. Furthermore, in late-phase effectiveness clinical trials, women are followed
up over a minimum period of 12 months, and the use of effective contraceptive methods is essential to
avoid pregnancy during this entire time period.
Microbicide drugs in development are administered intravaginally with direct local effects, andmay
hence alter lower genital tract defences and potentially compromise pregnancy (both maternal and
fetal) outcomes. Measures, therefore, need to be taken to minimise incident pregnancies as discussed
above, to enhance safety in the advent of a breakthrough pregnancy, or both.Eligibility criteria
In order to minimise pregnancy rates and reduce the probability of investigational product
exposure to the unborn baby, various strategies from screening and baseline through to follow up and
exit visits have been used by different microbicide trials. To date, these strategies included pre-
specifying pregnancy-related eligibility criteria. Women who were either pregnant at screening or
those who intended falling pregnant at any time during the trial were excluded. It has been argued,
however, that screening out women based on self-reported pregnancy intentions alone might not be
an adequate strategy, as trials that recruited women with no pregnancy intentions over the trial
duration still had high pregnancy rates. All trials, with the exception of the MDP 301 trial,26 including
the Savvy/Ghana trial,9 which had the highest pregnancy rates, screened out women on the basis of
this criterion.
On the basis of the limited success with this particular criterion, it has been suggested that iden-
tifying other pregnancy predictors for inclusion in the screening criteria might improve pregnancy
prediction inmicrobicide trials. Halpern et al.,31 in an analysis of 6748women participating in four late-
phase microbicide trials, found multiparity, living with a man, and frequent unprotected sexual acts
S. Sibeko et al. / Best Practice & Research Clinical Obstetrics and Gynaecology 26 (2012) 473–486480aweek before enrolment to be associatedwith higher hazards of falling pregnant during the trial.31 The
risk of pregnancy was lower in older women, in those with a higher education and more sexual
partners, and when long-acting contraceptive methods and condoms were used. Blanchard et al.32
found an overlap of a significantly higher risk of pregnancy with young age and living with partner,
whereas Sibeko et al.22 found an overlap with the use of oral contraceptives and condom use. From
these three analyses, it might be appropriate to, therefore, recommend the baseline use of long-acting
contraceptive methods, young age and living with partner as pregnancy predictors in future micro-
bicide trials.
Safety and statistical integrity during trial conduct
Because of the unknown and often unquantifiable risk of harm to the unborn baby (teratogenicity)
should the mother fall pregnant while exposed to the investigational drug, strategies need to be
implemented to, as primary prevention, enhance contraceptive use and prevent unintended preg-
nancies in microbicide trials.6 Should a woman have a breakthrough pregnancy, however, a secondary
prevention measure is to minimise exposure to the study drug, particularly before embryogenesis
occurs, in order to protect the unborn baby. Minimising drug exposure would entail stopping product
use early in pregnancy, before embryogenesis. To achieve this, frequent pregnancy testing and product
withdrawal at the first pregnancy test have been used by some trials. Two problems arise with
pregnancy detection in the first trimester, namely: false positivity rates with chemical testing are high,
and fetal wastage during the first trimester of pregnancy is also high.33 Optimising precision of
pregnancy detection tests and streamlined testing algorithms to minimise false positivity and off-
product time is critical for efficient trial conduct.
One strategy has been to test enrolled participants on a monthly basis during their scheduled
study visits using a highly sensitive beta human chorionic gonadotropin urine test, and placing the
participant on immediate product hold should the pregnancy test prove positive. Use of highly
sensitive tests and frequent testing for timeous pregnancy diagnosis, however, may increase
detection of preclinical pregnancies (chemical pregnancies). Subsequent study product withdrawal
for pregnancies that would otherwise have been miscarried spontaneously thereby leads to falsely
high pregnancy rates and unnecessary time off product.33 These combined strategies have been
thought to be a significant contributor to elevated pregnancy rates and statistical sequelae,
particularly where a single positive pregnancy test is diagnostic of a pregnancy within a trial
setting (Table 3).31 Additionally, occurrence of false–positive and chemical pregnancies may raise
two ethical concerns: for some women, pregnancy diagnosis alone may result in stress and for
others this may be worsened by a sequential pregnancy loss. Chemical and false pregnancies may
therefore be of extreme duress to a woman who may have already been informed of a pregnancy
diagnosis.
In order to offset falsely elevated pregnancy rates, the Population Council’s Carraguard trial25
investigators conducted pregnancy testing on a quarterly basis, with the resultant pregnancy rate
of 8,4% at the end of the study.25 Alternatively, implementation of two or more successive pregnancy
confirmation tests after the first positive test adopted by CAPRISA 00410 was effective in detecting
early pregnancy losses, expediting product re-institution, and thereby reducing time off study
product. This strategy only had four out of 54 probable chemical and false pregnancy tests,22
a statistic that was much lower than the estimated 25% chemical pregnancy rates in a pop-
ulation.33 Schreiber et al.33 recommend carrying out a pregnancy test only after a missed period,
which would be similar to a normal clinical setting. This approach may only minimally increase
product exposure duration, as they showed that this method would add 12 days or less of in-utero
product exposure. Effectiveness of the latter strategy is in reducing false high pregnancy rates is
yet to be observed.
Lastly, the following have been effective in minimising time off product: (1) continued preg-
nancy testing for the first 3 months of pregnancy after the first positive test to exclude unrecog-
nised early preclinical pregnancy loss; (2) the former, combined with continued regular study visits
by pregnant participants for early detection of delivery and pregnancy termination; (3) and
immediate product re-institution at the occurrence of a negative test. Carrying out blood beta
Table 3
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S. Sibeko et al. / Best Practice & Research Clinical Obstetrics and Gynaecology 26 (2012) 473–486 483human chorionic gonadotropin quantitation in the advent of ambiguous urine results has also been
recommended.Sexual and reproductive health outcomes
Incident pregnancies are avoided in microbicide studies for safety of the women who fall pregnant
and their babies, but also for protection of a range of sexual and reproductive health functions. As
microbicides are currently in development with limited understanding of drug effects after intra-
vaginal administration and before sexual exposure, the full spectrum of potential toxicities to sexual
and reproductive abilities is not fully understood. It is important, therefore, that ongoing studies
systemically collect data in this regard.
Fertility may be compromised when sperm, exposed to study product during intercourse, is
compromised and thereby reduces its ability to fertilise an egg. After conception, because of direct
passage of the study product up through the cervical canal into the uterus, the drug may potentially
lead to pregnancy losses and preterm labour with continued drug use late into pregnancy. Embryos
that are conceived while the mother is using the study product may be harmed and the babies born
with anomalies.
The discovery that a microbicide induces miscarriages, reduces fertility, causes birth defects, and
compromises maternal health would likely doom its development. Important safeguards, therefore,
need to be implemented to minimise such incidents, and active monitoring during the trial to
detect any of these adverse events should be standard practice. Additionally, the pregnant state
may affect behaviour around study product use or efficacy and the virulence of HIV, which in
turn may increase incident HIV infections and complicate trial outcomes.34 Lastly, women may
electively terminate pregnancies out of concerns for teratogenicity or for fear of trial participation
termination.
Data are usually collected on pregnancy outcomes within microbicide trials, and include miscar-
riages, terminated pregnancies, preterm labour and full-term births, with and without a live birth.
These are then compared, for that particular community, with background rates to indirectly assess
the effect of the study drug on each of the outcomes, the results of which are discussed at the
protocol safety and monitoring team meetings and data and safety monitoring board meetings. With
most of the 1.74 billion reproductive-age females being sexually active, and a probability of
conception during unprotected coitus of three in 100,35 as many as 720 million conceptions may
occur each year.
Tsui et al.29 reported that, on the basis of population studies, most conceptions (60–70%) will be
spontaneouslymiscarried, leaving about 239million identified pregnancies, of which 136.2millionwill
progress to live births, 33 million being unwanted.29 An additional 46 million pregnancies will be
electively terminated. Anything in excess of the documented reproductive health outcomes for any
particular community needs to be investigated closely.
Not all clinical trials have systematically documented and reported data in this regard in the
previous trials (Table 3)31; however, for the trials that did, there have not been any concerning safety
effects on sexual and reproductive health outcomes. Of note, however, is that studies that systemati-
cally collected these data, such as CAPRISA 004,10 assessed babies once off in the immediate post-
partum period. It is recommended that trials yet to be implemented follow babies longitudinally for
prolonged periods of time.
Conclusion
Microbicide trials that recruit sexually active women in their reproductive age are fraught
with reproductive health issues. If these are inadequately addressed, they may compromise the
conduct of the trial and the integrity of the results. From this review, it is evident that, where
a structured programme is used to address contraception and pregnancy issues, pregnancy rates
are significantly lowered, the probability of harm to the unborn baby reduced, and time off
product minimised.
S. Sibeko et al. / Best Practice & Research Clinical Obstetrics and Gynaecology 26 (2012) 473–486484Where contraception is used to prevent pregnancy, uptake and use of contraceptive methods is
enhanced by ensuring that all methods are provided free on-site by trained study staff during intensive
and supportive counselling sessions at every study visit. Enrolment criteria require careful screening to
avoid, including women who are likely to become pregnant while on study; however, this might be
viewed as coercive by some if not implemented properly. Frequent testing for pregnancy at each visit
using sensitive tests, coupled with successive repeated testing after a single positive test, is effective in
early pregnancy detection while ensuring low false positive tests and continued pregnancy states.
Immediate product withdrawal at pregnancy diagnosis reduces the period of exposure to the drug by
the unborn baby, whereas immediate resumption in the postpartum period is effective in minimising
time lost off product.
Continued follow up throughout the pregnancy allows immediate detection of parturition and
assessment of pregnancy outcomes. The research gaps identified were numerous; however, one of the
greatest seems to be use of microbicides throughout pregnancy in order to ascertain safety of use in the
population who are also at risk of HIV acquisition.
Finally, although specific steps have been initiated to provide safety data on microbicides for
pregnant women and their babies, much more research needs to be carried out at the various stages of
pregnancy. Subsequent studies should follow up infants born after exposure to microbicides for pro-
longed periods after birth.Practice points
 Intravaginally appliedmicrobicides, as a female-initiated strategy, aim to empowerwomen to
protect themselves against HIV. Because microbicide trials enrol women in reproductive age
groups, these trials are fraught with reproductive challenges, which affect trial conduct and
integrity of results.
 Microbicide trials need to have intensive contraceptive and pregnancy management pro-
grammes to address challenges efficiently and adequately posed by incident pregnancies
during the trial.
 For contraceptive-related recommendations, trials need to aim for 100% contraceptive uptake
and use of highly effective contraceptive methods throughout the trial by:
specifying eligibility criteria, including use of contraceptive methods;
separating contraceptive curriculum, which includes intensive counselling;
providing contraceptive counselling at each visit by trained family planning staff;
respecting women’s choice of method;
providing a wide range of contraceptives on-site;
adequately and continuously documenting choice of method; and
diligently and regularly monitoring, reviewing and supporting contraceptive use of each
participant at each visit.
 Pregnancy-related recommendations: these trials need to aim for low pregnancy rates
and increased surveillance in order to diagnose pregnancies reliably and sufficiently
early, reduce time to pregnancy detection, detect subclinical pregnancies, and re-institute
product by:
specifying eligibility criteria, including pregnancy intentions;
testing for pregnancy at every visit;
using highly sensitive and specific pregnancy tests;
repeating tests successively in order to detect subclinical pregnancy losses;
continuously following up pregnant women until pregnancy outcome has been estab-
lished; and
providing clear guidelines on product withdrawal and re-institution.
Research agenda
 From the completed microbicide trials to date, increased pregnancy-related adverse
outcomes have not been reported. None of the trials implemented continued product use in
pregnancy. Consequently, the effects of using microbicides throughout pregnancy on the
mother and fetus is minimally understood. This is because, in clinical trials to date, the
product has been withdrawn immediately once pregnancy is diagnosed.
 Pregnant women continue to be sexually active in pregnancy, and incident infections have
been reported in late trimesters of pregnancy. We, therefore, need to design and conduct
research that addresses the following issues:
application of the microbicide intravaginally may alter the microbial vaginal milieu and
hence affect the local immune system. We need to understand the effect of microbicides
on fertility;
currently some microbicides are used pericoitally; the effect of microbicide use on the
woman’s ability to conceive needs to be understood;
does microbicide use around the time of conception increase the risk of miscarriage?
 The pharmacokinetics and pharmacodynamics of microbicides are not completely under-
stood; yet, these influence the effect of microbicides on pregnancy outcomes. Does micro-
bicide use in the first trimester increase the risk of fetal anomalies? Or after the first trimester
increase the risk of preterm labor? Or in pregnancy increase adverse maternal outcomes such
as haemorrhage?
 Antiretroviral-based microbicides may be absorbed systemically: is the microbicide appli-
cation adequate to use for prevention of mother-to-child transmission? What is the effect of
microbicide use on development of resistance?
 For serodicordant couples planning a pregnancy, can targeted periconceptual use of micro-
bicides be adequate to prevent both sexual and mother-to-child transmission?
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